A large international trial has reported that finerenone significantly slows the decline of kidney function in people with chronic kidney disease who do not have diabetes. The findings, published in The New England Journal of Medicine in July 2026, could meaningfully expand how and for whom the drug is used.
Breaking out of the diabetes box
Finerenone belongs to a class of drugs called non-steroidal mineralocorticoid receptor antagonists, which dampen a hormonal pathway that drives inflammation and scarring in the kidneys. Until now, its clinical story has been tied closely to diabetes: its earlier evidence base and approvals centered on patients with chronic kidney disease linked to type 2 diabetes. The FIND-CKD trial deliberately stepped outside that boundary to ask whether the same protective effect holds when diabetes is not part of the picture.
What the trial found
The answer, according to the published results, was yes. Among non-diabetic patients, finerenone slowed the loss of kidney function compared with standard care. In chronic kidney disease, the trajectory matters enormously: the slope at which filtration capacity declines determines whether—and how quickly—a patient progresses toward dialysis or transplantation. Flattening that slope, even modestly, can translate into years of preserved kidney function and a better quality of life.
Why clinicians are paying attention
Chronic kidney disease is common, frequently silent in its early stages, and stubbornly hard to treat. For decades the mainstays were blood-pressure control and drugs that block the renin-angiotensin system. More recently, SGLT2 inhibitors reshaped the field. Adding a mineralocorticoid receptor antagonist with evidence in non-diabetic patients would give nephrologists another distinct lever to pull.
- Drug class: non-steroidal mineralocorticoid receptor antagonist targeting inflammation and fibrosis.
- New population: chronic kidney disease patients without diabetes.
- Key result: a significant slowing of kidney function decline versus standard care.
The road ahead
Trial evidence is a starting point, not a finish line. Regulators and guideline committees will scrutinize the full data, including safety signals such as changes in blood potassium, which are a known consideration with this drug class. Physicians will also work out how finerenone fits alongside existing therapies rather than replacing them.
Still, the direction of travel is clear. The 2026 wave of kidney research—including a first-in-class approval this month for an immune-driven kidney disease and priority review for another therapy—signals a field finally accumulating options after years of stagnation. For the millions living with chronic kidney disease and no diabetes, the FIND-CKD results offer something that has been in short supply: evidence that their disease, too, can be slowed.